Item request has been placed!
×
Item request cannot be made.
×
Processing Request
[Therapy for non-muscle invasive bladder cancer: HP-NAP].
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Additional Information
- Transliterated Title:
La risposta immunitaria Th1 mediata nella terapia della neoplasia vescicale non muscolo invasiva: il ruolo di HP-NAP.
- Source:
Publisher: Sage Publications Country of Publication: United States NLM ID: 0417372 Publication Model: Print Cited Medium: Internet ISSN: 1724-6075 (Electronic) Linking ISSN: 03915603 NLM ISO Abbreviation: Urologia Subsets: MEDLINE
- Publication Information:
Publication: 2018- : Thousand Oaks, CA : Sage Publications
Original Publication: Treviso : Libreria Editrice Canova
- Subject Terms:
Immunotherapy*;
Adjuvants, Immunologic/
*therapeutic use ;
Angiogenesis Inhibitors/
*therapeutic use ;
Bacterial Proteins/
*therapeutic use ;
Carcinoma, Transitional Cell/
*therapy ;
Urinary Bladder Neoplasms/
*therapy;
Adjuvants, Immunologic/
administration & dosage ;
Administration, Intravesical ;
Angiogenesis Inhibitors/
administration & dosage ;
Animals ;
Bacterial Proteins/
administration & dosage ;
CD4-Positive T-Lymphocytes/
immunology ;
CD8-Positive T-Lymphocytes/
immunology ;
Carcinoma, Transitional Cell/
blood supply ;
Carcinoma, Transitional Cell/
drug therapy ;
Carcinoma, Transitional Cell/
immunology ;
Carcinoma, Transitional Cell/
pathology ;
Cell Movement/
drug effects ;
Helicobacter pylori/
chemistry ;
Humans ;
Lymph Nodes/
immunology ;
Lymphocytes, Tumor-Infiltrating/
drug effects ;
Mice ;
Mice, Inbred C57BL ;
Neoplasm Invasiveness ;
Neoplasm Proteins/
agonists ;
Neovascularization, Pathologic/
drug therapy ;
Toll-Like Receptor 2/
agonists ;
Tumor Burden ;
Urinary Bladder Neoplasms/
blood supply ;
Urinary Bladder Neoplasms/
drug therapy ;
Urinary Bladder Neoplasms/
immunology ;
Urinary Bladder Neoplasms/
pathology ;
Xenograft Model Antitumor Assays - Abstract:
Purpose: Patients with non-muscle invasive bladder cancer recurrence after 2 induction courses of BCG are eligible for radical cystectomy. So, in the last years research to discover new drugs for the management of non-muscle invasive bladder cancer recurrence after failure of first and second line therapy is ongoing. In accordance to the results obtained with BCG, whose mechanism depends on the induction of the T helper 1 (TH1) immune response, we investigated the activity of a Toll-like receptor (TLR) 2 ligand, named Helicobacter Pylori Neutrophil Activating Protein (HP-NAP), that we recently demonstrated being able of enhancing the differentiation of Th1 cells, both in vitro and in vivo, because of its ability to create an IL-12 enriched milieu.
Materials and Methods: We show here, in a mouse model of bladder neoplasm implants, that local administration of HP-NAP decreases tumor growth by inducing tumor necrosis.
Results: The result is joined up with a massive cluster of both CD4+ and CD8+ IFN-γ+ cells, within neoplasm and regional lymph nodes. It is of note that HP-NAP-treated tumors show also a reduced vascularization due to the anti-angiogenic activity of IFN-γ induced by HP-NAP.
Conclusions: The present study suggests that the activity of HP-NAP against urothelial tumor burden warrants subsequent in vivo studies.
- Accession Number:
0 (Adjuvants, Immunologic)
0 (Angiogenesis Inhibitors)
0 (Bacterial Proteins)
0 (Neoplasm Proteins)
0 (Tlr2 protein, mouse)
0 (Toll-Like Receptor 2)
0 (neutrophil-activating protein A, Helicobacter pylori)
- Publication Date:
Date Created: 20120424 Date Completed: 20121029 Latest Revision: 20201209
- Publication Date:
20240829
- Accession Number:
10.5301/RU.2012.9189
- Accession Number:
22522462
No Comments.